Feedback (FDBK) Share Price, News & Analysis

Company Overview

Feedback plc (AIM: FDBK) provides innovative software and systems through its trading subsidiary, Feedback Medical. Feedback liberates data and knowledge from multiple healthcare IT systems and delivers better workflows to enable clinicians to communicate, collaborate and provide the best healthcare for their patients. It connects care settings with diagnostic and other relevant data to drive better, faster, safer decision that improve outcomes for patients. By linking different clinical systems together into a seamless view of the patient, Feedback can streamline patient pathways and deliver a digital health and diagnostics record across multiple care providers. Bleepa® is a communication and collaboration platform that displays clinical results at a certified and regulated quality, which enables multi-disciplinary team working and diagnostic-enhanced advice and guidance. CareLocker® is a patient-facing platform that gives patients access and control over their diagnostic and other clinical data. The Company has a number of growth opportunities domestically and internationally across a range of public and private healthcare markets including the NHS. Our highly scalable software-as-a-service (SaaS) based model is expected to provide increasing levels of revenue visibility as the Company grows its customer base.

Key Stats

• Today's Range: 16.75 to 16.86
• 50-Day Range: 16.78 to 64.46
• 52-Week Range: 16 to 152.92
• Volume: 110,226 shs
• Average Volume: 50,418 shs
• Market Capitalization: £2.25 million
• P/E Ratio: N/A
• Dividend Yield: 4.56%
• Price Target: N/A
• Consensus Rating: N/A

FDBK Stock Analysis - Frequently Asked Questions

How have FDBK shares performed this year?

Feedback's stock was trading at GBX 67.50 at the beginning of the year. Since then, FDBK stock has decreased by 75.0% and is now trading at GBX 16.86.
View the best growth stocks for 2024 here.

How were Feedback's earnings last quarter?

Feedback plc (LON:FDBK) issued its earnings results on Tuesday, February, 18th. The company reported ($26.00) EPS for the quarter. Feedback had a negative net margin of 279.16% and a negative trailing twelve-month return on equity of 35.63%.

When did Feedback's stock split?

Feedback's stock reverse split on Friday, October 14th 2022. The 1-200 reverse split was announced on Friday, October 14th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 14th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of Feedback?

Shares of FDBK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Feedback own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Feedback investors own include 4D pharma (DDDD), Omega Diagnostics Group (ODX), Quadrise Fuels International (QFI), Advanced Oncotherapy (AVO), B&M European Value Retail (BME), Coats Group (COA) and genedrive (GDR).

Company Calendar

• Last Earnings: 2/18/2020
• Today: 12/22/2024

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Health Information Services
• Sub-Industry: N/A
• Current Symbol: LON:FDBK
• CUSIP: N/A
• CIK: N/A
• Web: www.fbk.com
• Phone: +44-1954-718072
• Fax: N/A
• Employees: 24
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-3,300,000.00
• Net Margins: -279.16%
• Pretax Margin: N/A
• Return on Equity: -35.63%
• Return on Assets: -22.99%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.13
• Quick Ratio: 18.41

Sales & Book Value

• Annual Sales: £1.18 million
• Price / Sales: 1.90
• Cash Flow: GBX 15.06 per share
• Price / Cash Flow: 1.12
• Book Value: GBX 57 per share
• Price / Book: 0.30

Miscellaneous

• Outstanding Shares: 13,330,000
• Free Float: N/A
• Market Cap: £2.25 million
• Optionable: Not Optionable
• Beta: 0.77